Michael ZoererSenior Group Leader, Clinical Operations at AOP Orphan Pharmaceuticals AG
Michael is responsible for a team of 11 people and the overall delivery of the conducted studies. The group runs several studies in different indications with a clear focus on rare diseases. In 2016 AOP Orphan received approval for one new product (RAPIBLOC®). In 2019 AOP received the marketing authorization for their first biological (BESREMi®), after completing a series of clinical studies and successfully passing a series of EMA inspections under Michael’s responsibility.
Before joining AOP Orphan Michael has been operations manager for Haemophilia at Baxter.
Michael has many years of experience as a project manager and learned the job in clinical research from scratch starting as CRA at Amgen.
Michael received his Ph. D in biochemistry from the University of Vienna.